Solventum (NYSE:SOLV – Get Free Report) updated its FY 2024 earnings guidance on Friday. The company provided earnings per share guidance of 6.300-6.500 for the period, compared to the consensus earnings per share estimate of 6.240. The company issued revenue guidance of -.
Solventum Price Performance
Shares of SOLV traded up $1.93 during midday trading on Friday, reaching $60.59. The stock had a trading volume of 2,411,871 shares, compared to its average volume of 2,188,416. The company has a current ratio of 1.81, a quick ratio of 1.33 and a debt-to-equity ratio of 2.16. The business has a 50-day moving average price of $54.12. Solventum has a 12-month low of $47.16 and a 12-month high of $96.05.
Solventum (NYSE:SOLV – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.10. The firm had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.05 billion. The firm’s quarterly revenue was up .2% compared to the same quarter last year. Equities analysts predict that Solventum will post 6.25 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on SOLV
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
See Also
- Five stocks we like better than Solventum
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- MarketBeat Week in Review – 8/5 – 8/9
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- The Significance of Brokerage Rankings in Stock Selection
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.